Recently, we observed that suppression of tumor xenograft growth by silibinin was associated with reduction in tumor vasculature and an increased apoptosis. Here, we provide evidence for molecular events associated with antiangiogenic efficacy of pharmacologically achievable doses of silibinin in endothelial cell culture system. Our data show that silibinin almost completely (Po0.001) inhibits growth of human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC-dermal origin) together with induction of cell death in a dose-and time-dependent manner. Growth inhibition was associated with a strong induction of G1 arrest accompanied by an increase in Kip1/p27, Cip1/p21 and p53. Apoptosis induction (up to 14-to 17-fold in both cell lines, Po0.001) was an underlying mechanism in silibinin-induced death of endothelial cells. In the studies elucidating the molecular events involved in apoptosis, silibinin caused loss of mitochondrial membrane potential and an increase in cytochrome c release from mitochondria. An increase in Bax and a decrease in Mcl-1 proteins were also observed. Silibinin-induced apoptosis involved both caspase-dependent and -independent mechanisms. Silibinin also decreased survivin level and inhibited Akt and NF-jB signaling. Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-independent activation of NF-jB. Further, silibinin showed a concentration-dependent strong inhibition of capillary tube formation on matrigel, retraction and disintegration of preformed capillary network, inhibition of matrigel invasion and migration, and a decrease in matrix metalloproteinase-2 secretion by HUVEC. Together, these findings identify pleiotropic mechanisms for antiangiogenic efficacy of silibinin, and suggest its usefulness in angioprevention and antiangiogenic therapy.
Introduction
Angioprevention and antiangiogenic therapy are considered as efficient strategies for controlling the growth and metastasis of solid tumors as well as for other diseases involving pathological angiogenesis (Gimbrone et al., 1972; Carmeliet and Jain, 2000; Tosetti et al., 2002; . The emphasis and significance of antiangiogenic research could be exemplified by the intense involvement of many researchers in the last decade, which resulted into the clinical trials of more than two dozens of antiangiogenic drugs that are currently under different phases of evaluation in human patients (Kerbel, 2000) . Mechanisms of angiogenesis have been studied extensively, which seems to be different in pathological conditions in adults when compared with embryo development (Carmeliet and Jain, 2000; Ruoslahti, 2002) . There are many steps which are critical for angiogenesis and determine blood capillary formation including vasodilation, endothelial permeability, periendothelial support, endothelial cell proliferation, migration, survival, organization and remodeling into three-dimensional network of tubular structure (Carmeliet and Jain, 2000; Carmeliet, 2002; Ruoslahti, 2002) . It is logical that antiangiogenic efficacy of a compound will be directly correlated with the number of these steps being targeted by the agent.
Many studies have suggested that activation of Akt pathway including other mitogenic and survival signaling are critical for the growth, survival and migration of endothelial cells (Kim et al., 1993; Qi et al., 1999; Carmeliet, 2002; Chen et al., 2004; Gingis-Velitski et al., 2004; Gu et al., 2004) . Nuclear factor kappa B (NF-kB), a hetrodimeric transcription factor, is known to modulate the transcription of genes responsible for the growth and survival as well as inhibition of apoptosis (Baldwin, 1996; Baeuerle and Baltimore, 1996; Levkau et al., 1999; Malyankar et al., 2000; Yamamoto and Gaynor, 2001) . Survivin, an inhibitor of apoptosis protein (IAP), is also known for cell survival that directly inhibits caspase activation, and is also associated with caspase-independent apoptosis (O'Connor et al., 2000; Shin et al., 2001; Tran et al., 2002; Altieri, 2003) . Matrix metalloproteinases (MMPs) facilitate the migration and invasion of endothelial cells by degrading tissue matrix, which is a prerequisite for tissue remodeling leading to growth and development of new blood vessels (Jiang et al., 2000b; Li et al., 2003) . Inhibition of these molecular events severely affects growth, survival, migration, invasion and reorganization of endothelial cells, which could form the basis for antiangiogenic drug development. Extensive studies have provided evidence for positive correlation between different stages of tumor progression and tumor microvessel density (Brawer, 1996; van Moorselaar and Voest, 2002) . Many studies have also established the prognostic significance of microvessel density in several cancers such as prostate, colon, lung and breast (Brawer, 1996; Ali et al., 2001; van Moorselaar and Voest, 2002) . All these reports suggest a critical role of angiogenesis in tumor growth and development.
Antiangiogenic therapy (preventive/therapeutic inhibition of tumor angiogenesis) is suggested as one of the most promising approaches to control cancer, as endothelial cells are generally nontransformed cells and less prone to acquire drug resistance (Boehm et al., 1997; Carmeliet and Jain, 2000; Brekken et al., 2002; Tosetti et al., 2002; . Based on this assumption, identification of nontoxic agents having a direct or an indirect effect on pathological angiogenesis is an important area of research that would lead to the development of angiopreventive and/or antiangiogenic drugs for clinical uses against cancer. Further, this might prove to be a significant tool in the prevention of cancer growth and metastasis, and in reducing the risk of cancer. Based on this hypothesis, we evaluated the antiangiogenic efficacy and associated mechanisms of silibinin (Figure 1a) in human endothelial cells. The selection of silibinin for these studies was based on our recently completed studies, where we observed that silibinin-caused inhibition of human prostate tumor xenograft growth was associated with increased apoptosis and inhibition of tumor angiogenesis . In many animal studies, we did not observe any apparent toxicity of oral administration of silibinin, in addition other studies have shown its hepatoprotective, cardioprotective and nephroprotective effects against various toxins (Wellington and Jarwis, 2001; Singh et al., 2002; . It is also known to inhibit growth and survival of many types of cancer cells derived from skin, prostate, breast, lung, cervix, colon, blood and pancreas Agarwal, 2003, 2004) , and is already in clinic as hepatoprotective drug as well as used as dietary supplement in the United States and Europe (Wellington and Jarwis, 2001) .
Results

Silibinin strongly inhibits growth and induces apoptotic death of human endothelial cells
To study the growth inhibitory and apoptotic effects of silibinin on human endothelial cells, we used human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC) grown in medium containing 5% fetal bovine serum (FBS) and growth supplements. Silibinin (25-100 mM) treatment of HUVEC for 24, 48 and 72 h resulted in 28-56, 65-87 and 78-93% (Po0.01-0.001) decrease in total cell number as compared to control, respectively (Figure 1b After 24, 48 and 72 h of treatments, cells were harvested and counted with hemocytometer as described in 'Materials and methods'. Data presented for HUVEC and HMVEC are mean7s.e. of three and two individual samples for each treatment, respectively, from a single experiment. SB, silibinin; $, Po0.01; *Po0.001 inhibition, respectively (Figure 1c ). During determination of cell growth inhibition, we also observed deathinducing effect of silibinin by trypan blue dye exclusion method (data not shown). Further, we evaluated the possible apoptotic cell death effect of silibinin by annexin V-propidium iodide staining and flow cytometry analysis, in which only annexin V-stained cells were considered as apoptotic cells (Figure 2a , lower right chamber). Silibinin (25-100 mM) treatment for 24, 48 and 72 h caused 3-5, 18-42 and 53-57% (Po0.05-0.001) apoptotic cell death in HUVEC ( Figure 2b) ; and 2-28, 19-51 and 53-69% (Po0.01-0.001) apoptotic cell death in HMVEC (Figure 2c) , respectively, as compared to controls showing only 2-4% apoptotic cell death in both the cell lines (Figure 2 ). In HUVEC, 10 mM dose of silibinin did not show any considerable apoptotic effect; however, cell growth inhibition was observed (data not shown).
Silibinin induces a strong G1 arrest together with an upregulation of Kip1/p27, Cip1/p21 and p53 in endothelial cells
To study whether growth inhibitory effect of silibinin on endothelial cells is accompanied by cell cycle arrest, both HUVEC and HMVEC were treated with silibinin in exactly similar conditions as in cell growth assay. Cells were harvested and stained with saponin-propidium iodide, and analysed by flow cytometry for cell cycle distribution. Silibinin caused a strong dose-dependent increase in G1 arrest together with a concomitant decrease in S phase population in both cell lines (Figure 3 ). In HUVEC, silibinin treatment at 25, 50 and 100 mM doses for 24 h caused 58% (Po0.01), 71% (Po0.001) and 82% (Po0.001) cells in G1 phase as compared to control showing 51%, respectively (Figure 3a) . Conversely, S phase cell population was decreased to 21% (Po0.001), 13% (Po0.001) and 4% (Po0.001) as compared to control having 29%, respectively (Figure 3a) . A moderate decrease in G2-M phase cell population was also observed with the increase in silibinin doses (Figure 3a ). These effects of silibinin were sustained even after 48 and 72 h of treatment (data not shown). A time-dependent increase in G1 arrest was also observed at 10 mM dose of silibinin (data not shown). In HMVEC, 25, 50 and 100 mM silibinin treatment for 24 h caused 53%, 64% (Po0.05) and 72% (P ¼ 0.01) cells in G1 phase as compared to control showing 52%, respectively ( Figure 3b ). S phase cell population was decreased to 27%, 19% (Po0.05) and 10% (P ¼ 0.01) as compared to control showing 28%, respectively ( Figure 3b) . A moderate decrease in G2-M phase population was also observed at higher doses. However, in contrast to HUVEC, a moderate effect on G2-M arrest after 48 h, and both S and G2-M arrests after 72 h of silibinin treatment were observed in HMVEC (data not shown). Overall, these results suggested the role of cell cycle arrest in silibinin-induced growth inhibition of human endothelial cells. Further, to investigate molecular events associated with cell cycle arrest, we analysed the critical regulators of cell cycle progression, such as cyclin-dependent kinase inhibitors (Kip1/p27 and Cip1/p21) and p53, by immunoblotting in HUVEC after 24 h of silibinin treatment. A strong increase in the protein levels of Kip1/p27, Cip1/p21 and p53 were observed, which were in accord to the effect of silibinin on G1 arrest (Figure 3c ). Equal protein loading was confirmed by reprobing the membrane with b-actin (Figure 3c ).
Silibinin disrupts mitochondrial membrane potential (Dc m ) and releases cytochrome c
The damage of mitochondrial integrity or the loss of Dc m is an early event in the initiation and activation of apoptotic cascades (Marchetti et al., 1996; Green and Reed, 1998) . To determine whether silibinin-induced apoptosis in endothelial cells involves mitochondrial disruption, we examined the depolarization of mitochondrial membrane by measuring the fluorescence emission shift (red to green) of the Dc m sensitive cationic JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzamidazolocarbocyanin iodide) dye in HUVEC. Cells were treated with 10-50 mM doses of silibinin for 24 h, and at the end of treatments, cells were processed and stained with JC-1 dye and analysed by flow cytometry. Silibinin-treated cells showed an increase in green/red fluorescence intensity indicative of mitochondrial membrane depolarization. Quantification of JC-1 monomers (green fluorescence)/JC-1 dimers (red fluorescence) ratio showed a significant dose-dependent increase following silibinin treatment accounting for upto four-fold increase (Po0.01) as compared to control (Figure 4a ). Valinomycin (10 mM) was used as positive control that showed 5.6-fold increase in JC-1 monomer/dimer ratio (data not shown).
The role of mitochondrial damage in apoptosis is suggested to be mediated by the release of cytochrome c. Therefore, we investigated cytochrome c release from mitochondria by immunohistochemical analysis using cytochrome c specific primary antibody and Alexa 488-conjugated secondary antibody (Figure 4b ). Cells were treated with 10-50 mM doses of silibinin for 48 h before immunohistochemical staining. A very less diffused and less intense staining pattern of cytochrome c was observed in control cells, which is more indicative of its mitochondrial localization (Figure 4b, control) . In silibinin-treated cells, a dose-dependent more intense and marked diffuse staining pattern was observed, suggestive of cytochrome c release from mitochondria into the cytosol (Figure 4b ). To further support this observation, in similar treatments, immunoblot analysis was performed in cytosolic fraction. Consistent with microscopic observation, a dose-dependent increase in cytochrome c level in cytosol was observed; however, it was not detectable at 10 mM dose of silibinin (Figure 4c After 24 h of treatment, cells were harvested and stained with saponin-propidium iodide, and analysed for cell cycle distribution by flow cytometry as described in 'Materials and methods'. (c) HUVEC were treated with different doses of silibinin for 24 h and total cell lysates were prepared as described in 'Materials and methods'. Cell lysates were analysed by immunoblotting using specific antibodies for Kip1/p27, Cip1/p21, p53 and b-actin protein levels as described in 'Materials and methods'. Data shown is representative of a single experiment. Data presented for HUVEC and HMVEC in (a) and (b) are mean7s.e. of three and two individual samples for each treatment, respectively, from a single experiment. SB, silibinin; #, Po0.05; $, Po0.01; *Po0.001
and a decrease in Mcl-1 protein levels without any considerable effect on Bcl-2 ( Figure 4d ). Overall, these observations suggested the involvement of mitochondrial membrane potential dissipation and cytochrome c release from mitochondria into cytosol in silibinin-induced apoptosis in endothelial cells. Cytochrome c release from mitochondria into cytosol is shown to be a key event in the initiation and activation of caspase cascade involving caspase 3 and caspase 7 for the execution of apoptosis (Li et al., 1997; Green and Reed, 1998) , which was investigated next.
Silibinin causes both caspase-dependent and -independent apoptosis
Based on increased apoptosis and dissipation of mitochondrial membrane potential and cytochrome c release into cytosol in silibinin-treated cells, our next aim was to examine the involvement of caspases that play a major role in execution of apoptotic events. Accordingly, we investigated the levels of cleaved active subunits of pro-caspases (executioner caspases 3 and 7) by Western immunoblotting in cell lysates following 48 h of (10-50 mM) silibinin treatment. Silibinin caused a prominent increase in the cleaved subunits of caspase 3 (17 and 19 kDa) and caspase 7 (20 kDa) ( Figure 5a ). Next, we examined the effect of silibinin-caused caspases activation on PARP cleavage, which is one the downstream substrates of caspase cascade and a reliable marker of apoptosis. Caspases separate N-terminal DNA-binding domain of PARP from its C-terminal catalytic domain (89 kDa) by their cysteine protease activity (Kaufmann et al., 1993) . As expected, silibinin decreased total PARP (116 kDa) with a concomitant Overall, these results suggested the activation of caspases and PARP cleavage together with mitochondrial damage and cytochrome c release in silibinin-induced apoptotic death of endothelial cells. These effects were very strong at 50 mM dose of silibinin, which is pharmacologically achievable in animal studies .
Further studies were performed to delineate the role of caspases activation in silibinin-caused apoptosis of endothelial cells. Cells were 2 h pretreated with pan caspase inhibitor (CI, 100 mM z-VAD-fmk) followed by (50 mM) silibinin treatment for 48 h in the presence of CI, and thereafter, cells were harvested for FACS analysis of annexin V-stained cells as well as caspase 3 activity assay. Our data show that CI did not completely reverse silibinin-induced apoptosis ( Figure 5b) ; however, in similar treatment conditions a complete inhibition of silibinin-induced caspase activity (as measured by caspase 3 activity) by CI pretreatment was observed ( Figure 5c ). As expected, consistent with apoptosis induction and cleavage of caspase-3, silibinin also strongly activated caspase-3 as observed by its increased cysteine protease activity for tetrapeptide substrate linked with chromophore p-nitroanilide (DEVDp-NA) ( Figure 5c ). Overall, these results suggest the involvement of both caspase-dependent and -independent mechanisms in silibinin-induced apoptosis of endothelial cells.
Silibinin decreases protein level of survivin
In mammalian cells, apoptosis is mainly modulated by mitochondrial proteins and members of the IAP family of proteins (Altieri, 2003) . Survivin is a unique protein of IAP family, which is known to mediate regulation of cell death, cell cycle progression and microtubule stability. Recently, it was reported that survivin directly regulates caspases 3 and 7 by inhibiting their activation; however, downregulation of survivin also causes caspase-independent apoptosis via mitotic catastrophe (Okada and Mak, 2004) . Since, we observed both a strong activation of caspase 3 and 7, as well as caspaseindependent apoptosis by silibinin, next we assessed whether it also downregulates survivin levels. In the Western analysis following 48 h of silibinin treatment, we observed that silibinin decreases the level of survivin protein, and the effect was very strong at high dose of silibinin causing almost complete loss in survivin levels ( Figure 6a, panel 1) . Further, we observed that in caspase-inhibiting conditions, silibinin causes more decrease in survivin protein level, suggesting its possible role in caspase-independent apoptosis (data not shown). Silibinin did not show any noticeable change in the housekeeping protein b-actin, which was used as a loading control (Figure 6a , panel 2).
Silibinin inhibits Akt activation
Overexpression and activation of Akt is known for cell survival response, which modulates many downstream 
h
Figure 5 Effect of silibinin on caspases activation and caspaseindependent apoptosis in HUVEC. (a) Cells were treated with different doses of silibinin for 48 h as indicated in the figure, and total cell lysates were prepared and analysed for the protein levels of cleaved-caspase 3, cleaved-caspase 7, total-PARP, cleaved-PARP and b-actin using specific primary antibodies by immunoblotting as described in 'Materials and methods'. Antibody for PARP detected both total-PARP and high level of cleaved-PARP (panel 3), however, when same membrane was stripped and reprobed with specific cleaved-PARP antibody, detection of lower levels of cleaved-PARP at 10 and 25 mM doses of silibinin was also evident (panel 4). (b, c) Cells were treated with 100 mM z-VAD-fmk (CI-100) and/or 50 mM silibinin (Sb-50) for 48 h; in combination treatment CI was added 2 h prior to silibinin treatment as described in 'Materials and methods'. At the end of treatment, cells were harvested and analysed for apoptosis (b) or cell extracts were prepared for caspase 3 activity assay (c) as described in 'Materials and methods'. Data shown in (b, c) are mean of triplicate samples and representative of two individual experiments effectors for survival as well as antiapoptotic responses. Accordingly, we investigated the effect of silibinin on the levels of phospho-Akt (both ser473 and thr308) and total Akt levels by immunoblotting. Lower (10 and 25 mM) silibinin doses showed a slight inhibitory effect on both ser473 and thr308 phosphorylation of Akt without any change in total Akt protein level (Figure 6b ). At 50 mM dose, silibinin strongly decreased Akt phosphorylation at both ser473 and thr308 sites, and also showed a slight decrease in total Akt level ( Figure 6b ). Membrane was stripped and reprobed with b-actin as loading control (Figure 6b ). These results suggested an inhibitory effect of silibinin on Akt pathway in endothelial cells.
Silibinin inhibits NF-kB pathway
NF-kB family of transcription factors is known to regulate numerous genes responsible for cell growth and survival (Baeuerle and Baltimore, 1996; Levkau et al., 1999; Malyankar et al., 2000; Yamamoto and Gaynor, 2001) . To examine the effect of silibinin on activation of NF-kB, HUVEC were treated with various silibinin doses (0, 10, 25 and 50 mM) for 48 h, and nuclear and cytosolic extracts were prepared. Nuclear extract was analysed by EMSA for NF-kB DNA binding activity, which was strongly inhibited at 50 mM dose of silibinin ( Figure 7a ). Further, we analysed p50 and p65 subunits of NF-kB in nuclear and cytosolic extracts by immunoblotting to assess the possible inhibitory effect of silibinin on NF-kB translocation from cytosol to nucleus. Silibinin decreased nuclear levels of both p50 and p65, and this effect was very strong at 50 mM dose (Figure 7b , panels 1 and 2). At 10-25 mM dose of silibinin, a moderate dose-dependent increase in cytosolic p50 level was observed; however, at higher dose it was comparable to control ( Figure 7b , panel 3). In case of cytosolic p65, a strong decrease was observed at 50 mM dose of silibinin (Figure 7b , panel 4). Consistent with these results, a dose-dependent increase in IkBa level was observed at 10-25 mM doses of silibinin, which decreased strongly at 50 mM dose (Figure 7b , panel 5).
Since there are evidences for feedback regulation for IkBa expression by NF-kB, as IkBa is an NF-kB responsive gene (Hoffmann et al., 2002) , our results suggest that at lower doses silibinin inhibits NF-kB signaling by inhibiting nuclear translocation of NF-kB subunits; however, at high doses it decreases both cytosolic as well as transcriptionally active (nuclear) p65 followed by a decrease in IkBa level in endothelial cells.
We also used pan caspase inhibitor (CI, 100 mM) to assess whether it has any effect on silibinin caused inhibition of NF-kB DNA binding activity. CI alone did not affect NF-kB DNA binding activity, nor it reversed silibinin-caused inhibition of NF-kB activation (Figure 7c ). The specificity of the band was confirmed by supershift assay using anti-p50 and anti-p65 antibodies, and competition with unlabeled oligo (Figure 7c ). This observation suggests that inhibition of NF-kB pathway in caspase inhibiting condition could be associated with silibinin-induced caspase-independent apoptosis of endothelial cells.
NF-kB activation is independent of Akt activation in HUVEC
Some recent studies in cell culture system have shown that NF-kB activation is mediated via Akt pathway (Kitaura et al., 2000; Madrid et al., 2000; Mayo et al., 2003) . Since in the present study we observed that silibinin inhibits both Akt and NF-kB pathways, to investigate the possibility that NF-kB inhibition involves the upstream inhibition of Akt, an experiment was designed using wortmannin (10 mM), a phosphoinositide-3 kinase (PI3K) inhibitor that is an upstream kinase responsible for Akt activation. As shown in Figure 7c , in EMSA analysis wortmannin did not inhibit NF-kB DNA binding activity (Figure 7c ). To further support this observation, we performed an additional experiment including another PI3K inhibitor, LY292004 (LY, 10 mM) together with wortmannin. Consistent with the previous result, wortmannin did not show any considerable effect on NF-kB DNA binding activity; however and surprisingly, LY strongly inhibited NF-kB DNA binding activity, which was also evident in wortmannin plus LY combination (Figure 7d ). To confirm whether the dose of PI3K inhibitors used was enough to inhibit Akt phosphorylation, in the similar treatment, cell lysates were analysed for Akt activation by immunoblotting. The 10 mM dose of both wortmannin and LY was sufficient to completely inhibit Akt (ser473) phosphorylation without any change in total Akt protein levels (Figure 7e ). These results suggest that (1) NF-kB activation is independent of Akt activation; and (2) LY has different target/s from that of wortmannin, the inhibition of which by LY is directly associated with the inhibition of NF-kB activation in HUVEC.
Silibinin inhibits and disrupts capillary tube formation on matrigel
To study the effect of silibinin on in vitro angiogenesis, HUVEC were seeded in 24-well culture plates precoated with matrigel. In the first protocol, silibinin treatment started at the time of seeding HUVEC onto Matrigel, and cellular morphology was observed over a period of time. Silibinin inhibited capillary tube formation in a dose-as well as time-dependent manner.
A dose-dependent (10-50 mM) inhibition of capillary tube formation at 18 h of treatment is depicted in Figure 8a . The quantification of capillary tubes/well showed 36% (P ¼ 0.002), 46% (Po0.001) and 82% (Po0.001) decrease following 10, 25 and 50 mM silibinin treatment for 18 h, respectively (Figure 8b ). In the second protocol, silibinin treatment was carried out after 6 h of HUVEC seeding when rudimentary tubes were already formed. In quantitative estimation (after 24 h of HUVEC seeding), silibinin (10, 25 and 50 mM for 18 h) showed 26% (P ¼ 0.004), 44% (Po0.001) and 66% (Po0.001) decrease in capillary tubes/well, respectively (Figure 8c ). These observations suggest that silibinin inhibits capillary tube organization as well as disrupts preformed capillary tubes by HUVEC on matrigel. P labeled NF-kB specific oligonucleotide by EMSA as described in 'Materials and methods'. (b) Nuclear and cytosolic extracts were analysed for p50, p65, IkBa and b-actin protein levels by immunoblotting, as described in 'Materials and methods'. (c) Cells were treated with 100 mM pan caspase inhibitor z-VAD-fmk (CI) and/or 50 mM silibinin (CI was added 2 h prior to SB in CI þ SB) or 10 mM wortmannin for 48 h, and nuclear extracts were prepared and analysed for NF-kB DNA binding activity by EMSA. Samples were incubated with anti-p50 and anti-p65 antibodies for super shift assay, and excess unlabeled oligo for competition (Comp) as described in 'Materials and methods'. (d, e) Cells were treated with 10 mM wortmannin (Wort) and/or 10 mM LY294002 (LY) for 48 h, and nuclear and cytosolic extracts were prepared. (d) Nuclear extract was analysed for NF-kB DNA binding activity by EMSA as described in 'Materials and methods'. (e) Cytosolic extract was analysed for phospho-Akt (ser473) and total Akt using specific antibodies by immunoblotting as described in 'Materials and methods'. Data shown are representative of a single experiment 
Silibinin inhibits matrigel invasion and migration by endothelial cells and decreases matrix metalloproteinase-2 (MMP-2) activity in conditioned medium
To study the effect of silibinin on invasion and migration by endothelial cells, HUVEC were plated in cell culture inserts containing a thin layer of matrigel basement membrane matrix onto 8 mm pore size PET membrane. Cells were treated with 10-50 mM doses of silibinin in FBS and growth supplement-free medium for 24 h. Medium containing 5% FBS and growth supplements (chemoattractants) were added in companion (lower) chambers. After 24 h of treatment, a strong dose-dependent decrease in migrated cells on the lower side of the PET membrane was observed (Figure 8d) . Quantification of cells in five randomly selected areas of triplicate samples under Â 400 microscopic field showed 120.474.9, 81.074.6, 57.973.6 and 28.172.2 cells in control, 10, 25 and 50 mM silibinin-treated wells, respectively. The inhibition of matrigel invasion and migration by 10, 25 and 50 mM doses of silibinin accounted for 33% (Po0.01), 52% (Po0.001) and 77% (Po0.001), respectively ( Figure 8e ). Further, we observed that HUVEC treatment with silibinin for 24 h causes a decrease in secreted MMP-2 (72 kDa gelatinase A) as detected by gelatin zymogram analysis of conditioned media (Figure 8f ). In this regard, agents inhibiting MMP-2 secretion are known for their strong potential to suppress angiogenesis.
Discussion
The central finding of present study is that silibinin exhibits pleiotropic antiangiogenic effects in human endothelial cells. The data obtained suggest that silibinin strongly inhibits growth and causes apoptotic death of human endothelial cells. Silibinin-induced growth inhibition was accompanied by a strong G1 arrest involving upregulation of Kip1/p27, Cip1/p21 and p53. Silibinin-induced apoptosis in endothelial cells involves: (a) dissipation of mitochondrial membrane potential; (b) cytochrome c release from mitochondria into cytosol; (c) an increase in Bax and a decrease in Mcl-1; and (d) activation of caspases and PARP cleavage. Silibinin also decreased the protein level of survivin, the most important inhibitor of apoptosis protein (IAP). In order to define the role of caspase pathway in silibinin-caused apoptosis, the pretreatment of endothelial cells with pan caspase inhibitor z-VAD-fmk showed that silibinininduced apoptosis involves both caspase-dependent and -independent mechanisms. Further silibinin inhibited Akt signaling by inhibiting phosphorylation of Aktser473 as well as Akt-thr308. Silibinin also inhibited NF-kB DNA binding activity, which was accompanied by the inhibition of nuclear translocation p65 and p50 subunits, and an increase in IkBa; however, higher dose of silibinin downregulated both p65 as well as IkBa. Pan caspase inhibitor did not reverse silibinin-caused downregulation of survivin and NF-kB, suggesting their possible role in caspase-independent apoptotic effect of silibinin in endothelial cells. Consistent with the inhibitory effect of silibinin on in vivo tumor microvessel density in tumor xenograft , in the present study we observed that silibinin (a) inhibits capillary tube formation on matrigel; (b) disrupts preformed capillary network; (c) inhibits matrigel invasion and migration; and (d) inhibits MMP-2 secretion by HUVEC. Together, these findings provide a mechanistic rationale for the observed antiangiogenic efficacy of silibinin in in vitro cell culture in the present study as well as in vivo growing tumors as reported earlier . Cell cycle progression is controlled by various cyclindependent kinases, which are critically regulated by cyclin-dependent kinase inhibitors (CDKI) Kip1/p27 and Cip1/p21 as well as tumor suppressor p53 (Xiong et al., 1993; Toyoshima and Hunter, 1994; Grana and Reddy, 1995; Hofseth et al., 2004) . In G1 cell cycle arrest, CDKI binds with CDK-cyclin complexes (CDK2, 4 and 6-cyclin D and E) and inhibit their kinase activity for retinoblastoma (Rb) and Rb-related proteins, the hypophosphorylated forms of which sequester E2Fs in cytoplasm thereby inhibiting the expression of E2F growth responsive genes critical for G1-S check point transition (Paggi et al., 1996; Hofseth et al., 2004) . p53 is also known to regulate the expression of Cip1/p21 (Hofseth et al., 2004) . Therefore, silibinininduced levels of Kip1/p27, Cip1/p21 and p53 provide molecular evidence for its growth inhibitory effect through inhibition of cell cycle progression or induction of G1 arrest in endothelial cells.
Disruption of Dc m is known as an early event in apoptotic induction and linked to the release of cytochrome c from mitochondria to the cytosol (Marchetti et al., 1996; Green and Reed, 1998) . In the present study, we used a mitochondrial membrane potential sensitive cationic JC-1 dye that in the absence of, or at low Dc m , exists as monomer, emitting fluorescence at B525 nm; however, at higher Dc m or intact mitochondria, it forms 'J-aggregates' that emit at 590 nm (Cossarizza et al., 1993) . Silibinin showed a significant dissipation of Dc m as evidenced by the increase in JC-1 monomer to JC-1 dimer ratio. Mitochondria is a key regulator of apoptosis which integrate different proapoptotic pathways via release of cytochrome c into the cytosol (Green and Reed, 1998) . The damage of Dc m was accompanied by the release of cytochrome c from mitochondria to cytosol, as evidenced by immunohistochemical staining and immunoblotting. Bcl-2 family members also play an important role in apoptosis induction through mitochondria (Gross et al., 1999; Cory et al., 2003) . In this regard, silibinin moderately increased proapoptotic Bax and decreased antiapoptotic Mcl-1 protein levels. The released cytochrome c is known to form complex with Apaf-1 and pro-caspase 9 for caspase 9 activation that further initiates the activation of caspase cascade leading to activation of caspases 3 and 7, and other biochemical changes associated to apoptosis (Li et al., 1997; Green and Reed, 1998; Saelens et al., 2004) . Consistent with this, silibinin strongly increased caspase 3 and 7 activity as well as PARP cleavage in endothelial cells. In defining the role of caspases activation in silibinin-induced apoptosis of endothelial cells, we observed that it also involves caspase-independent mechanisms, which could possibly involve the downregulation of survivin and inhibition of Akt and NF-kB pathways.
Targeting PI3K-Akt as well as NF-kB, the major survival pathways, is suggested as potential mechanisms for apoptotic cell death induction. There are many reports suggesting that identification of inhibitors of Akt pathway could be very critical for developing novel therapeutic strategies directed at neoplasms exhibiting Akt activation, which also holds true for inhibiting the survival of endothelial cells in inhibition of pathological angiogenesis such as tumor angiogenesis . Consistent with these suggestions, we observed that silibinin inhibits Akt activation (phosphorylation of both ser473 and thr308 sites of Akt) which was strongly associated with the inhibition of survival or induction of apoptosis in endothelial cells.
NF-kB family of transcription factors is known to participate in the regulation of numerous genes that are required for cell growth and survival (Baldwin, 1996; Baeuerle, 1998) . NF-kB is a heterodimer, mostly composed of p50 and p65 subunits and retained in the cytoplasm as an inactive form through interaction with IkB inhibitory proteins, such as IkBa (Baeuerle and Baltimore, 1996) . In response to growth/survival/ antiapoptotic stimuli, IkBa gets phosphorylated by an upstream kinase (IKKa), and further ubiquitinated and degraded facilitating the nuclear translocation of NF-kB for its transcriptional activity (Zandi and Karin, 1999) . NF-kB is emerging as a critical cell survival factor and it also activates a number of antiapoptotic genes (Waddick and Uckun, 1999) . Consistent with these reports, silibinin inhibited NF-kB DNA binding activity, which was accompanied by the inhibition of nuclear translocation of NF-kB (p50 and p65) together with an increase in IkBa in cytosol as well as an overall decrease in p65 subunit. Inhibitory effect of silibinin on NF-kB pathway is further supported by its similar effect on immortalized endothelial cells (Yoo et al., 2004) . The decrease in p65 protein level at higher doses of silibinin could be either via downregulation of gene expression and/or via increased degradation of the protein, which needs further investigation in future studies. Activated caspases are shown to cleave p65 subunit leading to loss of carboxy-terminal transactivation domains to promote apoptosis (Levkau et al., 1999) . These authors also show that an uncleavable, caspase-resistant p65 protects cells from apoptosis. Therefore, in the present study, the loss of p65 could be most likely mediated via silibinininduced caspases activation.
There are reports that NF-kB activation is mediated by PI3K/Akt pathway in many cell types (Ozes et al., 1999; Li and Sarkar, 2002; Gustin et al., 2004) . Silibinin inhibited both Akt and NF-kB activation in HUVEC; therefore, by using inhibitors of PI3K (wortmannin and LY294002), we further investigated whether inhibition of NF-kB activation is mediated through the inhibition of Akt activation. Our data showed that inhibition of Akt activation by wortmannin did not inhibit NF-kB activation in HUVEC. This is further supported by the reports showing TNFa-induced NF-kB activation does not involve Akt activation in endothelial cells (Madge and Peber, 2000; Gustin et al., 2004) . Surprisingly, in contrast to wortmannin, LY294002 inhibited both Akt as well as NF-kB activation suggesting a different target/s of its action other than PI3K, which is upstream as well as directly/indirectly linked to the NF-kB pathway. In this regard, it has been reported that LY294002 also inhibits DNA-PK and mTOR (Brunn et al., 1996; Stiff et al., 2004) , which could be possible target/s for LY294002 to the upstream of NF-kB in endothelial cells. However, more studies are needed in future to test this hypothesis.
Neovascularity is an essential requirement in the progression of many cancers from latent and localized focal carcinomas to invasive carcinomas. Growth, invasion and migration of endothelial cells are critical in the organization of new blood capillaries in tumors (Carmeliet and Jain, 2000) . Migration of endothelial cells requires degradation of extracellular matrix by MMPs to facilitate the movement of endothelial cells. Therefore, inhibition of MMPs is also regarded as a critical target in suppression of endothelial cell migration, organization and, hence, angiogenesis (Jiang et al., 2000b; . Silibinin inhibited in vitro angiogenesis, which was accompanied by inhibition of invasion, migration and MMP-2 secretion by HUVEC. Together, these findings support the mechanism-based antiangiogenic efficacy of silibinin that could significantly contribute to angioprevention of cancer. Many antiangiogenic substances have been discovered and evaluated for their efficacy against growing solid tumors in laboratory studies, but only few of them including endostatin, TNP-470, SU5416, anti-vascular endothelial cell growth factor (VEGF) antibody and AG3340 could reach for clinical trial (Kerbel, 2000) . Most of the antiangiogenic agents are shown to inhibit either cell proliferation or induce apoptosis or suppress capillary tube organization by endothelial cells via targeting specific molecular events such as VEGF receptor signaling or MMP activity (Fotsis et al., 1997; Jones et al., 1999; Jiang et al., 2000a; Kerbel, 2000; Brakenhielm et al., 2001) . Growing tumors generally harbor multigenetic and -epigenetic aberrations leading to shift in equilibrium towards angiogenic microenvironment in the vicinity of tumor facilitating the recruitment of blood capillaries from the surrounding host tissue (Carmeliet and Jain, 2000; Rak et al., 2000) . Therefore, success of the antiangiogenic drug against neoplasm depends on a number of parameters and molecular events in endothelial cells as well as angiogenic tumor microenvironment, and that could be a reason why a drug targeting a particular such event is not effective in suppressing tumor growth or causing its regression. Here, we would like to mention that all the studies were carried out in complete growth supplement medium that contained IGF-1, EGF, TGFbeta, VEGF and PDGF together with FBS. Therefore, antiangiogenic mechanisms and efficacy of silibinin observed in the present study in cell culture systems is also likely to occur in in vivo systems; completed studies in human prostate tumor xenograft model further support this assumption.
In summary, pleiotropic antiangiogenic effects of silibinin involves growth inhibition, cell cycle arrest, apoptosis induction, inhibition of capillary tube organization, reduced invasion and migration of human endothelial cells. The molecular events associated with these effects includes upregulation of Kip1/p27, Cip1/ p21 and p53; mitochondrial apoptosis and caspases activation; downregulation of survivin and inhibition of Akt and NF-kB signaling; and inhibition of MMP-2 secretion as shown in Figure 9 . Additionally, we also observed that NF-kB activation is independent of Akt pathway; however, it was linked with LY294002 target/s other than PI3K in HUVEC. Together, these findings provide a mechanistic rationale for the development of silibinin as an angiopreventive/antiangiogenic agent for clinical use.
Materials and methods
Cell lines and reagents
HUVEC and HMVEC were from Clonetics (Walkersville, MD, USA). Cells were cultured in EGM-2 supplemented with 5% FBS and growth supplements (EGM-2 MV bullet kit) (Walkersville, MD, USA) under standard culture conditions (371C, 95% humidified air and 5% CO 2 ). Complete Cocktail of protease inhibitors was from Roche Molecular Biochemicals (Indianapolis, IN, USA). All caspases and cleaved poly (ADP-ribose) polymerase (PARP) primary antibodies, and peroxidase-conjugated secondary antibody were from Cell Signaling Technology (Beverly, MA, USA). Total PARP antibody was from BD Pharmingen (San Diego, CA, USA). Pan caspase inhibitor was from Enzyme Systems Products (Livermore, CA, USA). ApoTarget kit for caspase 3 activity assay was from BioSource International, Inc. (Camarillo, CA, USA) Annexin V/propidium iodide (PI) and JC-1 staining kits were from Molecular Probes (Eugene, OR, USA). Primary mouse anti-cytochrome c monoclonal antibody was from PharMingen (San Diego, CA, USA). Goat Alexa 488-conjugated anti-mouse IgG secondary antibody was from Molecular Probes Inc. (Eugene, OR, USA). Bio-Rad DC protein assay kit was from Bio-Rad laboratories (Hercules, CA, USA). ECL detection system was from Amersham Corp. (Arlington Heights, IL, USA). Silibinin was from Sigma (St Louis, MO, USA) and dissolved in DMSO as stock solution. Similar DMSO concentration (0.01%, v/v) was present in each treatment. Matrigel was from Fisher Scientific (Pittsburgh, PA, USA). PROTOCOL, HEMA3 kit was from Biochemical Sciences Inc. (Swedesboro, NJ, USA). Tris-glycine, gelatin and DNA retardation gels were from Invitrogen (Invitrogen, Gaithersberg, MD, USA).
Cell growth assay
HUVEC and HMVEC cells were seeded (5000 cells/cm 2 ) in 60-and 35-mm culture dishes, respectively, in EGM-2 medium containing FBS and growth supplements. Next day, cells were treated with different doses of silibinin (0, 25, 50 and 100 mM doses) for 24, 48 and 72 h. At the end of each treatment, total cells were collected by a brief trypsinization and counted with hemocytometer. Trypan blue dye was used for assessing dead cells.
Here, we would like to mention that silibinin doses used in the present study are well within the range of pharmacologically achievable concentrations in animal study without any adverse health effect. In a recently completed study, we observed that oral feeding of silibinin at 333-2000 mg/kg/day dose for 16 days results in upto B165 mM silibinin concentration in plasma of mice without any apparent toxicity . No evidence of toxicity has been reported in rats and dogs when the drug was chronically administered for 12 months at 50-2500 mg/kg/day doses. There are many studies in humans showing consumption of silymarin/silibinin upto 55 mg/kg/day effectively treats liver diseases and toxicity without any adverse health effect; however, plasma levels of the drug are not reported.
Quantitative apoptosis assay
Silibinin-induced apoptotic death of HUVEC and HMVEC was quantified by annexin V and PI staining and flow cytometry, as described recently . Briefly, after silibinin treatment (0, 25, 50 and 100 mM for 24, 48 and 72 h), cells were collected and washed with PBS twice, and subjected to annexin V and PI staining using Vybrant Apoptosis Assay Kit2 following the step-by-step protocol provided by the manufacturer. Recombinant annexin V conjugated to fluorophores and the Alexa fluro 488 dye provides maximum sensitivity for the detection. After staining, flow cytometry was performed for the quantification of apoptotic cells using core facility of University of Colorado Cancer Center.
FACS analysis for cell cycle distribution
HUVEC and HMVEC cells were seeded (5000 cells/cm 2 ) in EGM-2 medium containing FBS and growth supplements. Next day, cells were treated with different doses of silibinin (0, 25, 50 and 100 mM doses) for 24, 48 and 72 h. At the end of each treatment, total cells were collected by a brief trypsinization followed by processing for cell cycle analysis as reported recently . Briefly, cells were suspended in 0.5 ml of saponin/PI solution (0.3% saponin (w/v), 25 mg/ml PI (w/v), 0.1 mM EDTA and 10 mg/ml RNase (w/v) in PBS), and incubated over night at 41C in dark. Cell cycle distribution was then analysed by flow cytometry using FACS analysis core facility of University of Colorado Cancer Center. Finally, percentage of cells in different phases of cell cycle was determined by ModFit LT cell cycle analysis software.
Immunoblot analysis
HUVEC cells were treated with silibinin (0, 10, 25 and 50 mM) for 24 h for the analysis of cell cycle regulators and for 48 h for other studies, and cell lysates were prepared in nondenaturing lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.3 mM phenyl methyl sulfonyl fluoride, 0.2 mM sodium orthovanadate, 0.5% NP-40, 5 U/ml aprotinin) as described recently . Protein concentration in lysates was determined using Bio-Rad DC protein assay kit by Lowry method. For immunoblot analyses, 70-100 mg of protein lysates per sample were used as described recently . Membranes were probed for desired proteins using specific primary antibodies followed by peroxidase-conjugated appropriate secondary antibody, and visualized by ECL detection system.
Mitochondrial membrane potential (Dc m ) analysis
JC-1 is most widely applied for detecting mitochondrial depolarization occurring in the early stages of apoptosis (Cossarizza et al., 1993) . Alterations in Dc m were analysed by flow cytometry using the mitochondrial membrane potential sensitive cationic dye JC-1 and following vendor's protocol with some modification. Briefly, HUVEC were treated with desired doses of silibinin, and at the end of treatment, cells were harvested and washed with PBS. Cells were incubated with JC-1 (10 mg/ml in PBS) at 371C for 10 min. Stained cells were washed with PBS twice and analysed by Becton Dickinson FACScan System at flow cytometry core facility of University of Colorado Cancer Center. Valinomycin (10 mM) was used as positive control. Forward scatter vs side scatter was used to gate the viable population of cells. JC-1 exhibits potential-dependent accumulation in mitochondria, indicated by a florescence emission shift from green to red. The emission wavelengths of JC-1 monomers and 'J-aggregates' were B525 (FL-1 channel) and B590 (FL-2 channel) nm.
Immunohistochemical subcellular localization of cytochrome c HUVEC were seeded on four-well chamber slides and next day treated with desired doses of silibinin for 48 h. At the end of the treatment, cells were fixed with methanol at À201C for 10 min and washed twice with ice-cold PBS. Cells were gradually rehydrated with PBS and then incubated with 10% BSA in PBS for 30 min at room temperature. Cells were rinsed twice with PBS and incubated with primary mouse anticytochrome c monoclonal antibody in PBS with 3% BSA at 41C overnight. Cells were then rinsed in PBS with 3% BSA six times and incubated with goat Alexa 488-conjugated antimouse IgG secondary antibody in PBS with 3% BSA for 1 h. Cells were then rinsed in PBS with 3% BSA six times and observed and photographed under inverted Nikon TE-300 microscope with an epifluorescent attachment equipped with a Princeton Instrument Micromax camera, at 488 nm fluorescence excitation and 520 nm fluorescence emission. Images are acquired with Image Pro-plus software (Media Cybernetics, Silver Spring, MD, USA).
Preparation of cytosolic extract for immunoblot analysis of cytochrome c
At the end of silibinin treatment, cells were washed with icecold PBS and collected by a brief trypsinization followed by two more wash with PBS. The cell pellet was resuspended in 200 ml of extraction buffer containing 210 mM manitol, 70 mM sucrose, 20 mM HEPES-KOH, pH 7.4, 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM dithiothreitol, 0.1 mM PMSF and protease inhibitors. After 20-min incubation on ice, cells were homogenized with a glass Dounce and pestle, and resulting homogenates were left on ice for an additional 20 min. Homogenates were centrifuged at 10 000 g for 15 min at 41C, and resulting supernatant was further centrifuged at 18 000 g for 30 min at 41C, to yield cytosolic extract. In total, 70 mg protein per sample was resolved on 16% SDS-PAGE and transferred onto nitrocellulose membrane followed by blocking in 5% (w/v) nonfat dry milk in TBS. Membrane was probed with anti-cytochrome c antibody overnight at 41C followed by 1 h incubation with HRP-conjugated secondary antibody. The protein was visualized by ECL detection system.
Caspase activity assay
Caspase 3 activity was assayed by colorimetric protease assay ApoTarget kit following the manufacturer's protocol. Briefly, HUVEC were treated with silibinin (10, 25 and 50 mM) and/or pan caspase inhibitor (50 mM) for 48 h, cells were collected and cell lysates prepared in cell lysis buffer (tris buffered saline containing detergent). In total, 100 mg of protein lysate per sample was mixed with 2 Â reaction buffer and 100 mM substrate (DEVD-pNA), and incubated at 371C for 2 h in dark. These assay conditions were standardized and products of the reaction remain in the linear range of detection after 2 h of incubation. Developed color in reaction was measured at 405 nm in microplate reader, and blank readings (samples without substrates) were subtracted from each sample reading before calculation.
Electrophoretic mobility shift assay (EMSA)
HUVEC were treated with different doses of silibinin (10-50 mM) or pan caspase inhibitor (50 mM) or wortmannin (10 mM) or LY294002 (10 mM) or their combination as desired for 48 h, and nuclear and cytosolic extracts were prepared as published recently . In case of inhibitor plus silibinin treatment, inhibitor was added in the media 2 h before silibinin treatment and continued for 48 h with silibinin. For EMSA, NF-kB-specific oligonucleotide (3.5 pmol) was end-labeled with g-32 P-ATP (3000 Ci/mmol at 10 mCi/ml) using T 4 polynucleotide kinase in 10 Â kinase buffer as per the manufacturer's protocol (Promega, Madison, WI, USA). Labeled double-stranded oligo probe was separated from free g-32 P-ATP using G-25 Sephadex column. Consensus sequences of oligonucleotide were 5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 and 3 0 -TCA ACT CCC CTG AAA GGG TCC G-5 0 . In total, 8 mg protein from nuclear extracts was incubated with 5 Â gel shift binding buffer (20% glycerol, 5 mM MgCl 2 , 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCl and 0.25 mg/ml poly dI-dC Á poly dI-dC) and then with 32 P end-labeled NF-kB consensus oligo nucleotide for 20 min at 371C. In supershift and competition assays, sample was incubated with anti-p65 or anti-p50 antibody or unlabeled-oligo before addition of 32 P end-labeled NF-kB oligo. DNA-protein or DNA-protein-antibody complexes thus formed were resolved on 6% DNA retardation gels. The gel was dried and bands were visualized by autoradiography.
In vitro angiogenesis assay on matrigel
For in vitro angiogenesis, HUVEC (40 000 cells/well) cells are seeded on matrigel, a reconstituted extracellular matrix preparation of EHS mouse sarcoma, onto which they differentiate and form capillary-like structures. This process requires cell-matrix interaction, intercellular communication and cell mobility similar to in vivo tumor angiogenesis. To examine the effect of silibinin on in vitro angiogenesis, two protocols were employed. In first protocol, HUVEC were simultaneously seeded with silibinin (0, 10, 25 and 50 mM) in 24-well culture plates precoated with Matrigel, and tube formation was observed periodically over time under a phase contrast microscope. Quantitative data and pictures are shown for 18 h of silibinin treatment. In the second protocol, silibinin treatment was carried out 6 h after HUVEC seeding when rudimentary capillary network was formed. Quantitative data are shown for 18 h of silibinin treatment.
Endothelial cell invasion and migration assay BD BioCoatt Matrigel Invasion Chamber was used to assess the effect of silibinin on invasive potential of HUVEC in response to serum and growth supplements. HUVEC were plated (in complete medium) in cell culture inserts containing a thin layer of matrigel basement membrane matrix onto an 8 mm pore size PET membrane. Cells were allowed to adhere for 3 h, and then treated with different (0, 10, 25 and 50 mM) doses of silibinin in FBS and growth supplement-free medium for 24 h at 371C. At the same time, complete medium (5% FBS and growth supplements (namely; VEGF, EGF, PDGF and IGF-1; as chemo-attractants) was added in companion (lower) chambers. The absence of serum and growth supplements in the upper chamber results in a migration response towards the lower chamber. At the end of treatment, culture medium was removed from both upper and lower chambers, and membranes dried and fixed with methanol, and stained with hematoxylin and eosin using PROTOCOL, HEMA3 kit. To determine the number and percentage of cells that had migrated through the membrane pores, cells remaining on the top of the membrane were removed by gentle wiping with a cotton swab. The cells that had migrated to the lower surface of the filter were then counted under a microscope at Â 400 magnification.
Zymogram analysis for MMP-2 activity HUVEC were grown in 60 mm plates in complete medium to a subconfluent stage. Cells were then washed twice with PBS to remove spent medium, and treated with silibinin (0, 10, 25 and 50 mM) in serum-free medium containing growth supplements. After 24 h of treatment, conditioned medium was harvested and analysed for gelatinolytic activity on substrate gel. Total cells were collected for equilibrating the volume of conditioned medium for equal number of live cells in each treatment. Each sample was mixed with equal volume of tris-glycine SDS sample buffer (2 Â ) and kept at room temperature for 10 min, and then it was run on 10% zymogram (gelatin) gel. The gel was then processed by incubating in zymogram renaturing buffer for 30 min at room temperature followed by over night incubation in zymogram developing buffer at 371C and staining with Coomassie Blue. The areas of protease activity appeared as clear bands.
Statistical analysis
The data were analysed using Jandel Scientific SigmaStat 2.03 software. Student's t-test was employed to assess the statistical significance of difference between control and different treatment groups. A statistically significant difference was considered to be present at Po0.05.
Abbreviations HUVEC, human umbilical vein endothelial cells; HMVEC, human microvascular endothelial cells; VEGF, vascular endothelial cell growth factor; DC m , mitochondrial membrane potential; JC-1, 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzamidazolocarbocyanin iodide; PARP, poly(ADP-ribose) polymerase; z-VAD, benzyloxycarbonyl-Val-Ala-Asp; FMK, fluoromethyl-ketone; DEVD-pNA, Asp-Glu-Val-Asp-p-nitroanilide; NF-kB, nuclear factor kappa B; MMP-2, matrix metalloproteinase-2.
